NEW YORK, NY--(Marketwired - Aug 13, 2014) - Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors who purchased InVivo Therapeutics Holdings Corp. ("InVivo" or the "Company") (OTCQB: NVIV) securities between April 5, 2013 and August 26, 2013.
For more information, click here: http://zlk.9nl.com/invivo-therapeutics-nviv.
The complaint alleges that the Company misrepresented the time needed to submit testing data for its biopolymer scaffold product to the Food and Drug Administration. In particular, it is alleged that the Company stated it would be able to report results by the end of 2014 despite conditions set by the FDA that, unbeknownst to investors, would make meeting this deadline impossible.
If you suffered a loss in InVivo you have until October 6, 2014 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/invivo-therapeutics-nviv.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut, and Washington D.C. The firm's 26 attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.